| TAH Drug Code | OPLA |
|---|---|
| Indications | RA, Juvenile chronic arthritis, Systemic or discoid lupus erythematosus, Light-sensitive disease, Suppression of malaria. |
| Dosing | Other indications except malaria:Adults:Generally treated with lowest effective dose. 200mg or 400mg daily, maximum dose:6.5mg/kg/day(calculated with ideal body weight).Children:Should be treated with lowest effective dose, maximum dose:6.5mg/kg/day(calculated with ideal body weight).For children ideal body weight < 31kg, should avoid dose of 200mg tablet each time.Suppression of malaria:Adult 400 mg on the same day of each weeks. Children & infant 6.5 mg/kg body weight. Maximum: Adult dose regardless of wt. Suppressive therapy should begin 2 weeks prior to exposure. Failing this, in adults an initial double (loading) dose of 800 mg, or in children 12.9 mg/kg (maximum: 800 mg), may be taken in 2 divided doses, 6 hr apart. The suppressive therapy should be continued for 8 weeks after leaving the endemic area. Treatment of acute attack of malaria: Adult Initially 800 mg followed by 400 mg in 6-8 hours & 400 mg on each of 2 consecutive days. Alternatively, 800 mg as single dose. Infant & children first dose: 12.9 mg/kg (but not exceeding a single dose of 800 mg); 2nd dose: 6.5 mg/kg (but not exceeding 400 mg) 6 hours after first dose; 3rd dose: 6.5 mg/kg (but not exceeding 400 mg) 18 hours after 2nd dose; 4th dose: 6.5 mg/kg (but not exceeding 400 mg) 24 hours after 3rd dose. Total dose of 32 mg/kg body weight (not exceeding 2 g) over 3 days |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment required |
| Contraindications | Retinal or visual field changes. Long-term therapy in children. |
| Adverse Effects | Headache, GI complaints; skin reactions; psychic stimulation, bleaching of hair, alopecia, blurred vision, difficulty in focusing or accommodation, corneal changes, retinal changes; blood dyscrasias. |
| Pregnancy | No (Limited) Human Data – Probably Compatible |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |